Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Diagnosis and treatment of anemia in patients with inflammatory bowel disease.

Mücke V, Mücke MM, Raine T, Bettenworth D.

Ann Gastroenterol. 2017;30(1):15-22. doi: 10.20524/aog.2016.0083. Epub 2016 Sep 6. Review.

2.

RNA interference-based nanosystems for inflammatory bowel disease therapy.

Guo J, Jiang X, Gui S.

Int J Nanomedicine. 2016 Oct 12;11:5287-5310. eCollection 2016. Review.

3.

Iron Deficiency Is Common During Remission in Children With Inflammatory Bowel Disease.

Wikholm E, Malmborg P, Forssberg M, Hederos CA, Wikström S.

Glob Pediatr Health. 2016 Mar 4;3:2333794X16633672. doi: 10.1177/2333794X16633672. eCollection 2016.

4.

High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.

Dahlerup JF, Jacobsen BA, van der Woude J, Bark LÅ, Thomsen LL, Lindgren S.

Scand J Gastroenterol. 2016 Nov;51(11):1332-8. doi: 10.1080/00365521.2016.1196496. Epub 2016 Jun 21.

5.

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.

Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Büning C; AEGIS Study Group.

Aliment Pharmacol Ther. 2016 Aug;44(3):259-70. doi: 10.1111/apt.13665. Epub 2016 May 29.

6.

High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life.

García-López S, Bocos JM, Gisbert JP, Bajador E, Chaparro M, Castaño C, García-Erce JA, Gomollón F.

Blood Transfus. 2016 May;14(2):199-205. doi: 10.2450/2016.0246-15. Epub 2016 Apr 28.

7.

Management of Iron Deficiency Anemia.

Jimenez K, Kulnigg-Dabsch S, Gasche C.

Gastroenterol Hepatol (N Y). 2015 Apr;11(4):241-50.

8.

Comparison of the Efficacies of Parenteral Iron Sucrose and Oral Iron Sulfate for Anemic Patients with Inflammatory Bowel Disease in Korea.

Han YM, Yoon H, Shin CM, Koh SJ, Im JP, Kim BG, Kim JS, Jung HC.

Gut Liver. 2016 Jul 15;10(4):562-8. doi: 10.5009/gnl15373.

9.

The prevalence and clinical characteristics of anemia in Korean patients with inflammatory bowel disease.

Lee DS, Bang KB, Kim JY, Jung YS, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Choi KY, Park DI.

Intest Res. 2016 Jan;14(1):43-9. doi: 10.5217/ir.2016.14.1.43. Epub 2016 Jan 26.

10.

The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease.

Koduru P, Abraham BP.

Therap Adv Gastroenterol. 2016 Jan;9(1):76-85. doi: 10.1177/1756283X15616577. Review.

11.

Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Bonovas S, Fiorino G, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L, Danese S.

Medicine (Baltimore). 2016 Jan;95(2):e2308. doi: 10.1097/MD.0000000000002308. Review.

12.

Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease.

Martinelli M, Strisciuglio C, Alessandrella A, Rossi F, Auricchio R, Campostrini N, Girelli D, Nobili B, Staiano A, Perrotta S, Miele E.

J Crohns Colitis. 2016 May;10(5):566-74. doi: 10.1093/ecco-jcc/jjv242. Epub 2016 Jan 4.

13.

Five-Year Period Prevalence and Characteristics of Anemia in a Large US Inflammatory Bowel Disease Cohort.

Koutroubakis IE, Ramos-Rivers C, Regueiro M, Koutroumpakis E, Click B, Schwartz M, Swoger J, Baidoo L, Hashash JG, Barrie A, Dunn MA, Binion DG.

J Clin Gastroenterol. 2016 Sep;50(8):638-43. doi: 10.1097/MCG.0000000000000417.

14.

Iron deficiency anemia in inflammatory bowel disease.

Kaitha S, Bashir M, Ali T.

World J Gastrointest Pathophysiol. 2015 Aug 15;6(3):62-72. doi: 10.4291/wjgp.v6.i3.62. Review.

15.

Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients.

Borstlap WA, Buskens CJ, Tytgat KM, Tuynman JB, Consten EC, Tolboom RC, Heuff G, van Geloven AA, van Wagensveld BA, C A Wientjes CA, Gerhards MF, de Castro SM, Jansen J, van der Ven AW, van der Zaag E, Omloo JM, van Westreenen HL, Winter DC, Kennelly RP, Dijkgraaf MG, Tanis PJ, Bemelman WA.

BMC Surg. 2015 Jun 28;15:78. doi: 10.1186/s12893-015-0065-6. Erratum in: BMC Surg. 2015;15:110. van Geloven, N [corrected to van Geloven, A A W].

16.

Intravenous iron administration and hypophosphatemia in clinical practice.

Hardy S, Vandemergel X.

Int J Rheumatol. 2015;2015:468675. doi: 10.1155/2015/468675. Epub 2015 Apr 27. Review.

17.

The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease.

Koutroubakis IE, Ramos-Rivers C, Regueiro M, Koutroumpakis E, Click B, Schwartz M, Swoger J, Baidoo L, Hashash JG, Barrie A, Dunn MA, Binion DG.

Inflamm Bowel Dis. 2015 Jul;21(7):1587-93. doi: 10.1097/MIB.0000000000000417.

18.

A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease.

Reinisch W, Altorjay I, Zsigmond F, Primas C, Vogelsang H, Novacek G, Reinisch S, Thomsen LL.

Scand J Gastroenterol. 2015;50(10):1226-33. doi: 10.3109/00365521.2015.1031168. Epub 2015 Apr 21.

19.

Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Abhyankar A, Moss AC.

Inflamm Bowel Dis. 2015 Aug;21(8):1976-81. doi: 10.1097/MIB.0000000000000386. Review.

20.

Anemia in inflammatory bowel disease outpatients: prevalence, risk factors, and etiology.

Antunes CV, Hallack Neto AE, Nascimento CR, Chebli LA, Moutinho IL, Pinheiro Bdo V, Reboredo MM, Malaguti C, Castro AC, Chebli JM.

Biomed Res Int. 2015;2015:728925. doi: 10.1155/2015/728925. Epub 2015 Feb 1.

Supplemental Content

Support Center